Inactive Instrument

Analyst Reco. Dipexium Pharmaceuticals Inc Nasdaq

Equities

Oppenheimer Downgrades PLx Pharma to Perform From Outperform, Removes $11 Price Target	22-08-15	MT
JMP Securities Downgrades PLx Pharma to Market Perform From Market Outperform	22-08-15	MT
Raymond James Adjusts PLx Pharma's Price Target to $10 from $12, Keeps Outperform Rating	22-05-16	MT
Oppenheimer Adjusts PLx Pharma Price Target to $16 From $22, Maintains Outperform Rating	22-03-14	MT
Raymond James Adjusts PLx Pharma Price Target to $12 From $14, Maintains Outperform Rating	22-03-14	MT
Raymond James Upgrades PLx Pharma to Outperform From Market Perform; Price Target is $14	21-12-07	MT
PLX PHARMA : BWS Financial Initiates Coverage on PLx Pharma With Buy Rating, $29 Price Target	21-09-21	MT
PLX PHARMA : JMP Securities Adjusts PLx Pharma's Price Target to $21 From $12, Keeps Market Outperform Rating	21-07-20	MT
PLX PHARMA : Oppenheimer Adjusts PLx Pharma PT to $22 From $20, Maintains Outperform Rating	21-07-15	MT
PLX PHARMA : Oppenheimer Initiates PLx Pharma at Outperform Rating With $20 Price Target	21-04-09	MT

No results for this search